Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial
Primary result · Composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable anginaResult — go to the resultHazard ratio 0.99 95% CI 0.80–1.22Authors' conclusion
The results of this randomized clinical trial demonstrated that, for participants with chronic coronary disease, diabetes, and a previous MI, high-dose OMVM alone or in conjunction with EDTA-based chelation did not reduce cardiovascular events.
Study context
- Population
- Participants 50 years or older with diabetes and an myocardial infarction (MI) 6 weeks ago or morerandomized
- Participants
- 1,000 participants
- Comparison
- OMVM vs placebo
- Active OMVMn = 500
- Placebo OMVMn = 500reference
- Primary endpoint
- Composite of:
- All-cause mortality
- MI
- Stroke
- Coronary revascularization
- Hospitalization for unstable angina
- Follow-up
- Median (IQR) 48 (34-58) months
Methodological details88 sites in the US and Canada, 1:1:1:1 allocation ratio
- 88 sites in the US and Canada
- 1:1:1:1 allocation ratio
Primary result
As reported in the abstract
Hazard ratio
0.99
95% CI 0.80–1.22
P = 0.92
Events by treatment group
Active OMVMvs placebo OMVM
HR 0.99 (95% CI 0.80–1.22); P = 0.92
Further findings
| Outcome | EDTA chelation + active OMVM | EDTA chelation + placebo OMVM | Placebo infusion + active OMVM | Placebo infusion + placebo OMVM | HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|
| Primary end point, by factorial group · 5-year event rateActive infusion + active OMVMvs placebo infusion + placebo OMVM | 34.0% | 35.7% | 36.0% | 34.3% | 0.91 (0.67–1.23) | P = 0.54 | |
| 0.512Hazard ratio (log scale) |
MI, stroke, mortality from cardiovascular causes
- Nonsignificant, numerically higher event rate in the active OMVM compared to placebo OMVM group
Baseline characteristics
- Median (IQR) age
- 67 (60-72) years
- Male
- 730 (73%)
Original publication
Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial. JAMA Intern Med. Published 1 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →